Sulfacetamide–sulfur

Reviewed labels describe topical control of acne vulgaris, acne rosacea and seborrheic dermatitis. All selected records list unapproved drug other; they do not establish FDA-approved indications or an approved NDA/ANDA. Product selection requires clinician/pharmacist assessment.

This profile concerns skin combinations. Single-ingredient ophthalmic sulfacetamide, oral sulfonamides, other strengths and compounded products require their own review.

For 10%/5% cleanser and 9.8%/4.8% wash: wet skin, gently lather 10–20 seconds, rinse thoroughly and pat dry; once/twice daily or prescribed. Shorter contact/lower frequency may help dryness. Shake the selected 9.8%/4.8% product first.

Shake 10%/5% lotion; cleanse, then gently apply a thin layer 1–3 times daily or prescribed. Its concentration is stated per mL; this is not the gram-based cleanser instruction. No universal gram maximum or treatment duration is established.

Selected labels prohibit use with kidney disease, rather than providing an eGFR reduction. No validated hepatic/dialysis algorithm is supplied; topical administration does not eliminate systemic-risk assessment.

Known/suspected ingredient hypersensitivity and kidney disease prohibit selected products. Cleanser specifically includes sulfonamide/sulfur sensitivity. These are actual product restrictions; do not replace them with an invented renal threshold.

No boxed warning in the selected labels; this is not FDA confirmation of safety or approval. Serious hypersensitivity warnings remain clinically material.

Local redness, scaling, irritation and sensitization can occur. Serious reactions described partly draw on ophthalmic sulfacetamide reports; no reliable incidence for each reviewed skin combination is established.

Selected lotion/wash labels state incompatibility with silver preparations. No validated safe spacing rule is provided. Review other topical agents and irritation; no universal systemic CYP interaction algorithm is inferred.

Safety/effectiveness below 12 years are unestablished in selected full labels. No infant or geriatric-specific dosing formula is provided; assess comorbid disease, fragile skin and actual product.

Product reproductive studies are lacking; use in pregnancy only when clearly needed after benefit/risk assessment. Human milk transfer is unknown and caution is advised. Legacy letter categories do not quantify risk.

Kidney disease is an explicit no-use condition. Hepatic dose adjustment is unestablished; jaundice or systemic hypersensitivity symptoms warrant prompt evaluation.

Sulfacetamide competes with bacterial PABA-dependent folate synthesis. Sulfur’s acne mechanism is incompletely established; antimicrobial/keratolytic descriptions do not prove superiority to other therapies.

Skin absorption rate/extent is not adequately quantified. Reported 7–12.8-hour sulfacetamide half-life relates to systemic discussion, not a measured topical combination half-life. Do not infer zero absorption or an oral-dose conversion.

Assess irritation/sensitization and improvement. Larger damaged areas may warrant appropriate systemic observation/labs; no universal schedule is established. Stop and contact clinician for rash, fever, mouth sores, joint symptoms or worsening skin.

Use only as prescribed on skin, with the correct rinse/leave-on directions. Seek emergency assessment for severe skin/mucosal reactions, breathing difficulty or accidental overdose/ingestion. Keep away from children.

Selected 10%/5% cleanser 227 g: NDC 71335-2940-1; 10%/5% lotion 25 g: NDC 44523-602-01; 9.8%/4.8% wash 285 g: NDC 44523-748-10. These listing examples do not establish FDA approval or current stock.

10%/5% cleanser: 100 mg sodium sulfacetamide + 50 mg sulfur per gram. Selected lotion states those amounts per mL. 9.8%/4.8% wash: 98 mg + 48 mg per gram. Vehicle and route directions govern; do not make a density-based substitution.

Selected lotion/wash: 20–25°C, permitted 15–30°C excursions; protect from freezing/excess heat and close tightly. Cleanser repeats heat/freeze protection without a complete temperature table. No universal after-opening expiry is supplied.